Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2020
Event: Entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than periodic operating results. Key transaction metrics include:
- Gross Proceeds: Approximately $43.7 million.
- Shares Issued: Approximately 17.6 million shares of common stock.
- Price Per Share: $2.485.
- Warrants Issued: One warrant per share to purchase one share of common stock.
- Warrant Exercise Price: $2.36.
- Warrant Term: Five years from closing.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the increase in equity capital and the issuance of unregistered securities. The company entered into securities purchase agreements with existing and new institutional and accredited investors. No prior comparable period data is provided in this specific filing to assess operational changes.
Guidance, Outlook, and Obligations
- Registration Obligation: The Company must file a registration statement with the SEC to register the shares and warrant shares for resale within 60 days of closing.
- Effectiveness Timeline: The Company must use best commercially reasonable efforts to have the registration statement declared effective within 30 days of filing, or within 90 days if selected for review.
- Outlook: Proceeds are designated for working capital and general corporate purposes, implying support for ongoing operations and development.
Investor Verification Checklist
- Verify the closing date of the private placement to confirm the 60-day filing deadline for the resale registration statement.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants, redemption rights, or dilution protections.
- Confirm the exact number of shares issued and the final net proceeds after deducting transaction expenses.
- Monitor subsequent filings (e.g., S-1 or S-3) for the registration of the shares and warrants for public resale.